Re-epithelialization from human skin explant cultures is promoted by ligand-activated HER3 receptor

Journal of Dermatological Science

Volumn 59, Issue 1, 2010, Pages 7-15

  Forsberg, Sofi ^a   Rollman, Ola ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Epidermis; ErbB3 protein; Fluorescence microscopy; Neuregulin 1; Tyrosine kinase receptors

Indexed keywords

ANTINEOPLASTIC AGENT; CP 654577; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; MESSENGER RNA; NEU DIFFERENTIATION FACTOR; NEU DIFFERENTIATION FACTOR BETA 1; PERTUZUMAB; UNCLASSIFIED DRUG; HEREGULIN BETA1; LIGAND; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR;

ARTICLE; CELL PROLIFERATION; DIMERIZATION; EPIDERMIS; EPITHELIZATION; EXPLANT; FLUORESCENCE IMAGING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN CULTURE; TISSUE REGENERATION; TRANSACTIVATION; WESTERN BLOTTING; ADULT; AGONISTS; BIOSYNTHESIS; CULTURE TECHNIQUE; DRUG EFFECTS; FEMALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; REGENERATION;

ADULT; ANTIBODIES, MONOCLONAL; CULTURE TECHNIQUES; EPIDERMIS; FEMALE; HUMANS; LIGANDS; MIDDLE AGED; NEUREGULIN-1; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-3; REGENERATION; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 77953610737     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2010.03.017     Document Type: Article

References (51)

1. Jorissen R.N., Walker F., Pouliot N., Garrett T.P., Ward C.W., Burgess A.W. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003, 284:31-53.
2. Cohen S., Ushiro H., Stoscheck C., Chinkers M. A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. J Biol Chem 1982, 257:1523-1531.
3. Piepkorn M., Lo C., Plowman G. Amphiregulin-dependent proliferation of cultured human keratinocytes: autocrine growth, the effects of exogenous recombinant cytokine, and apparent requirement for heparin-like glycosaminoglycans. J Cell Physiol 1994, 159:114-120.
4. Prigent S.A., Lemoine N.R., Hughes C.M., Plowman G.D., Selden C., Gullick W.J. Expression of the c-erbB-3 protein in normal human adult and fetal tissues. Oncogene 1992, 7:1273-1278.
5. Press M.F., Cordon-Cardo C., Slamon D.J. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990, 5:953-962.
6. Piepkorn M., Predd H., Underwood R., Cook P. Proliferation-differentiation relationships in the expression of heparin-binding epidermal growth factor-related factors and erbB receptors by normal and psoriatic human keratinocytes. Arch Dermatol Res 2003, 295:93-101.
7. Stoll S.W., Kansra S., Peshick S., Fry D.W., Leopold W.R., Wiesen J.F., et al. Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes. Neoplasia 2001, 3:339-350.
8. Plowman G.D., Culouscou J.M., Whitney G.S., Green J.M., Carlton G.W., Foy L., et al. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 1993, 90:1746-1750.
9. Srinivasan R., Poulsom R., Hurst H.C., Gullick W.J. Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J Pathol 1998, 185:236-245.
10. Falls D.L. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 2003, 284:14-30.
11. Britsch S. The neuregulin-I/ErbB signaling system in development and disease. Adv Anat Embryol Cell Biol 2007, 190:1-65.
12. Lu H.S., Chang D., Philo J.S., Zhang K., Narhi L.O., Liu N., et al. Studies on the structure and function of glycosylated and nonglycosylated neu differentiation factors. Similarities and differences of the alpha and beta isoforms. J Biol Chem 1995, 270:4784-4791.
13. Marikovsky M., Lavi S., Pinkas-Kramarski R., Karunagaran D., Liu N., Wen D., et al. ErbB-3 mediates differential mitogenic effects of NDF/heregulin isoforms on mouse keratinocytes. Oncogene 1995, 10:1403-1411.
14. De Potter I.Y., Poumay Y., Squillace K.A., Pittelkow M.R. Human EGF receptor (HER) family and heregulin members are differentially expressed in epidermal keratinocytes and modulate differentiation. Exp Cell Res 2001, 271:315-328.
15. Bacus S.S., Huberman E., Chin D., Kiguchi K., Simpson S., Lippman M., et al. A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells. Cell Growth Differ 1992, 3:401-411.
16. Karamouzis M.V., Badra F.A., Papavassiliou A.G. Breast cancer: the upgraded role of HER-3 and HER-4. Int J Biochem Cell Biol 2007, 39:851-856.
17. Muraoka-Cook R.S., Caskey L.S., Sandahl M.A., Hunter D.M., Husted C., Strunk K.E., et al. Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1. Mol Cell Biol 2006, 26:6412-6424.
18. Sartor C.I., Zhou H., Kozlowska E., Guttridge K., Kawata E., Caskey L., et al. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol 2001, 21:4265-4275.
19. Regnier M., Asselineau D., Lenoir M.C. Human epidermis reconstructed on dermal substrates in vitro: an alternative to animals in skin pharmacology. Skin Pharmacol 1990, 3:70-85.
20. Rikimaru K., Moles J.P., Watt F.M. Correlation between hyperproliferation and suprabasal integrin expression in human epidermis reconstituted in culture. Exp Dermatol 1997, 6:214-221.
21. Lu H., Rollman O. Fluorescence imaging of re-epithelialization from skin explant cultures on acellular dermis. Wound Repair Regen 2004, 12:575-586.
22. Forsberg S., Ostman A., Rollman O. Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase. Arch Dermatol Res 2008, 300:505-516.
23. Forsberg S., Saarialho-Kere U., Rollman O. Comparison of growth-inhibitory agents by fluorescence imaging of human skin re-epithelialization in vitro. Acta Derm Venereol 2006, 86:292-299.
24. Johnson I. Fluorescent probes for living cells. Histochem J 1998, 30:123-140.
25. Memon A.A., Sorensen B.S., Melgard P., Fokdal L., Thykjaer T., Nexo E. Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients. Br J Cancer 2004, 91:2034-2041.
26. Beerli R.R., Graus-Porta D., Woods-Cook K., Chen X., Yarden Y., Hynes N.E. Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol Cell Biol 1995, 15:6496-6505.
27. Pinheiro J.C., Bates D.M. Mixed-effects models in S and S-PLUS 2000, Springer, New York.
28. Schelfhout V.R., Coene E.D., Delaey B., Waeytens A.A., De Rycke L., Deleu M., et al. The role of heregulin-alpha as a motility factor and amphiregulin as a growth factor in wound healing. J Pathol 2002, 198:523-533.
29. Nanney L.B., McKanna J.A., Stoscheck C.M., Carpenter G., King L.E. Visualization of epidermal growth factor receptors in human epidermis. J Invest Dermatol 1984, 82:165-169.
30. Adelsman M.A., McCarthy J.B., Shimizu Y. Stimulation of beta1-integrin function by epidermal growth factor and heregulin-beta has distinct requirements for erbB2 but a similar dependence on phosphoinositide 3-OH kinase. Mol Biol Cell 1999, 10:2861-2878.
31. Adam L., Vadlamudi R., Kondapaka S.B., Chernoff J., Mendelsohn J., Kumar R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem 1998, 273:28238-28246.
32. Jones J.T., Akita R.W., Sliwkowski M.X. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett 1999, 447:227-231.
33. Naidu R., Yadav M., Nair S., Kutty M.K. Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer 1998, 78:1385-1390.
34. Hayashi M., Inokuchi M., Takagi Y., Yamada H., Kojima K., Kumagai J., et al. High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res 2008, 14:7843-7849.
35. Yi E.S., Harclerode D., Gondo M., Stephenson M., Brown R.W., Younes M., et al. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. Mod Pathol 1997, 10:142-148.
36. Fuchs I., Vorsteher N., Buhler H., Evers K., Sehouli J., Schaller G., et al. The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma. Anticancer Res 2007, 27:959-963.
37. Krahn G., Leiter U., Kaskel P., Udart M., Utikal J., Bezold G., et al. Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. Eur J Cancer 2001, 37:251-259.
38. Wimmer E., Kraehn-Senftleben G., Issing W.J. HER3 expression in cutaneous tumors. Anticancer Res 2008, 28:973-979.
39. Stove C., Stove V., Derycke L., Van Marck V., Mareel M., Bracke M. The heregulin/human epidermal growth factor receptor as a new growth factor system in melanoma with multiple ways of deregulation. J Invest Dermatol 2003, 121:802-812.
40. Reschke M., Mihic-Probst D., van der Horst E.H., Knyazev P., Wild P.J., Hutterer M., et al. HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res 2008, 14:5188-5197.
41. Berger M.B., Mendrola J.M., Lemmon M.A. ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. FEBS Lett 2004, 569:332-336.
42. Li S., Schmitz K.R., Jeffrey P.D., Wiltzius J.J., Kussie P., Ferguson K.M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005, 7:301-311.
43. Agus D.B., Akita R.W., Fox W.D., Lewis G.D., Higgins B., Pisacane P.I., et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002, 2:127-137.
44. Franklin M.C., Carey K.D., Vajdos F.F., Leahy D.J., de Vos A.M., Sliwkowski M.X. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004, 5:317-328.
45. Graus-Porta D., Beerli R.R., Daly J.M., Hynes N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. Embo J 1997, 16:1647-1655.
46. Patel N.V., Acarregui M.J., Snyder J.M., Klein J.M., Sliwkowski M.X., Kern J.A. Neuregulin-1 and human epidermal growth factor receptors 2 and 3 play a role in human lung development in vitro. Am J Respir Cell Mol Biol 2000, 22:432-440.
47. Polosa R., Prosperini G., Tomaselli V., Howarth P.H., Holgate S.T., Davies D.E. Expression of c-erbB receptors and ligands in human nasal epithelium. J Allergy Clin Immunol 2000, 106:1124-1131.
48. Fedi P., Pierce J.H., di Fiore P.P., Kraus M.H. Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members. Mol Cell Biol 1994, 14:492-500.
49. Prigent S.A., Gullick W.J. Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera. Embo J 1994, 13:2831-2841.
50. Carraway K.L., Soltoff S.P., Diamonti A.J., Cantley L.C. Heregulin stimulates mitogenesis and phosphatidylinositol 3-kinase in mouse fibroblasts transfected with erbB2/neu and erbB3. J Biol Chem 1995, 270:7111-7116.
51. Yen L., You X.L., Al Moustafa A.E., Batist G., Hynes N.E., Mader S., et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 2000, 19:3460-3469.